CAD106 and BACE-1 Inhibitor

CAD106 and BACE-1 Inhibitor in Preclinical Alzheimer’s Disease Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease (Generation)

What is the Generation study?

A five year study of more than 1,300 cognitively healthy adults, ages 60 to 75, at high risk of developing symptoms of Alzheimer’s because they inherited two copies of the apolipoprotein E (ApoE4) gene - one from each parent.

What is the purpose of Generation?

The purpose of this study is to test whether two investigational drugs called CAD106 and CNP520, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at risk of developing clinical symptoms based on their age and genotype. Participants in the study will be randomly assigned to receive either the study medication or placebo – an inactive substance designed to look like a medication.

Eligibility

Men and women ages 60-75 years old who are cognitively normal carriers of two copies of the ApoE4 gene. Additional eligibility criteria and study information can be found at generationstudy.com.

 

If you are interested in learning more about the Generation study, please call (401) 455-6402 or send an email to memory@butler.org. Ask about the “Generation study.”

Organization
Butler Hospital

Area of Study
Memory and Aging

Status
Active

Click here to subscribe to our monthly Memory Matters e-newsletter >>

Contact Form

If you are interested in learning more about this study, please call (401) 455-6402 or fill out the form below.